Eunice Wang, MD

Dr. Eunice Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center.

Articles

Considerations for Venetoclax + Azacitidine Administration and AE Management

June 9th 2022

Richard Stone, MD, and Eunice Wang, MD, discuss considerations and challenges related to the administration of venetoclax and azacitidine in the community setting, and share strategies for managing adverse events associated with this combination.

Selecting the Right Patients for CPX-351 or Venetoclax + Azacitidine in AML

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, provide an overview of how patients with AML are selected for treatment with CPX-351 or the combination of venetoclax-azacitidine.

CPX-351 in Treatment of AML and Clinical Considerations

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, comment on the role of CPX-351 in the treatment of secondary AML and offer practice pointers for treatment with this drug, including management of adverse events.

Patient Profile 1: Patient with Secondary Acute Myeloid Leukemia

May 26th 2022

Two experts review a patient profile and discuss whether the patient meets the criteria for secondary acute myeloid leukemia (AML).

Secondary Acute Myeloid Leukemia (AML): Overview

May 26th 2022

Richard Stone, MD, and Eunice Wang, MD, define secondary acute myeloid leukemia treatment goals and how treatment has been affected by the COVID-19 pandemic.

Dr. Wang on the Potential Impact of Menin Inhibitors in AML

June 11th 2021

Eunice Wang, MD, discusses the potential impact of menin inhibitors on the treatment of acute myeloid leukemia.

Dr. Wang on Preliminary Findings From the KOMET-001 Trial in Relapsed/Refractory AML

December 15th 2020

Eunice Wang, MD, discusses preliminary findings from the ongoing KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML

February 20th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid leukemia.

Dr. Wang Discusses Treatment Options for FLT3-Mutated AML

February 9th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses treatment options for patients with FLT3-mutated acute myeloid leukemia.

Dr. Wang Discusses Crenolanib Plus Chemotherapy in AML

January 30th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia.

Dr. Wang Discusses FLT3 Mutations in AML

June 25th 2017

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia.